Latest Period
Q1 2026
Security Snapshot
Sensei Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SNSE) Institutional Ownership
CUSIP: 81728A207
13F Institutional Holders and Ownership History from Q1 2025 to Q1 2026
Institutions Reporting
30
Shares (Excl. Options)
2,156,465
Price
$31.52
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- SNSE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 2,156,465
- Total 13F value
- $67,971,428
- Portfolio coverage rank
- 0%
- Share change
- +2,094,161
- Value change
- +$66,014,101
- Number of holders
- 30
- Shares outstanding
- 25,898,756
- SEC-reported price per share
- $10.79
- Insider filing price
- $10.79
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- SNSE - Sensei Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 81728A207.
- 30 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 10 to 30 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $514,780 to $67,971,428.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 30 institutions filings for Q1 2026.
Security key
81728A207
Latest holder period
Q1 2026
13F holders
30
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
SNSE full holder history
Faeth Therapeutics, Inc. SEC filings
Faeth Therapeutics, Inc. company facts
Faeth Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 81728A207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
SNSE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| S2G Investments, LLC | 10% | $45,301,304 | 2,575,401 | S2G Investments, LLC | 15 Jun 2026 | |||
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.8% | $35,533,612 | 2,020,103 | Suvretta Capital Management, LLC | 15 Jun 2026 | |||
| STEMPOINT CAPITAL LP | 9.9% | $4,006,121 | 132,873 | StemPoint Capital LP | 31 Mar 2026 | |||
| Trails Edge Capital Partners, LP | 9.9% | $1,217,257 | 126,010 | Trails Edge Capital Partners, LP | 18 Feb 2026 | |||
| Caligan Partners LP | 9.4% | $3,798,960 | 126,002 | Caligan Partners LP | 31 Mar 2026 | |||
| MILLENNIUM MANAGEMENT LLC | 3.1% | -65% | $876,106 | -$1,838,176 | 41,561 | -68% | ICS Opportunities II LLC | 01 Jun 2026 |
As of 31 Mar 2026, 30 institutional investors reported holding 2,156,465 shares of Sensei Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SNSE). This represents 8.3% of the company’s total 25,898,756 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Latest
Q1 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,156,465 | $67,971,428 | +$66,014,101 | $31.52 | 30 |
| 2025 Q4 | 48,247 | $514,780 | -$10,572 | $10.67 | 10 |
| 2025 Q3 | 49,335 | $466,215 | -$168,686 | $9.45 | 9 |
| 2025 Q2 | 69,928 | $599,982 | +$593,398 | $8.58 | 10 |
| 2025 Q1 | 16,514 | $6,507 | +$6,507 | $0.39 | 1 |